Back to Search
Start Over
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
- Source :
-
Pharmacological research [Pharmacol Res] 2022 Oct; Vol. 184, pp. 106456. Date of Electronic Publication: 2022 Sep 16. - Publication Year :
- 2022
-
Abstract
- The development of tumor therapeutic resistance is one of the important reasons for the failure of antitumor therapy. Starting with multiple targets and multiple signaling pathways is helpful in understanding the mechanism of tumor resistance. The overexpression of prolyl isomerase Pin1 is highly correlated with the malignancy of cancer, since Pin1 controls many oncogenes and tumor suppressors, as well as a variety of cancer-driving signaling pathways. Strikingly, numerous studies have shown that Pin1 is directly involved in therapeutic resistance. In this review, we mainly summarize the functions and mechanisms of Pin1 in therapeutic resistance of multifarious cancers, such as breast, liver, and pancreatic carcinomas. Furtherly, from the perspective of Pin1-driven cancer signaling pathways including Raf/MEK/ERK, PI3K/Akt, Wnt/β-catenin, NF-κB, as well as Pin1 inhibitors containing juglone, epigallocatechin-3-gallate (EGCG), all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), it is better to demonstrate the important potential role and mechanism of Pin1 in resistance and sensitization to cancer therapies. It will provide new therapeutic approaches for clinical reversal and prevention of tumor resistance by employing synergistic administration of Pin1 inhibitors and chemotherapeutics, implementing combination therapy of Pin1-related cancer signaling pathway inhibitors and Pin1 inhibitors, and exploiting novel Pin1-specific inhibitors.<br />Competing Interests: Conflict of interest The authors declare that there is no potential competing interest.<br /> (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Subjects :
- Arsenic Trioxide therapeutic use
Humans
Mitogen-Activated Protein Kinase Kinases
NF-kappa B
NIMA-Interacting Peptidylprolyl Isomerase metabolism
Peptidylprolyl Isomerase metabolism
Peptidylprolyl Isomerase therapeutic use
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt
Tretinoin therapeutic use
beta Catenin
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Neoplasms drug therapy
Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1096-1186
- Volume :
- 184
- Database :
- MEDLINE
- Journal :
- Pharmacological research
- Publication Type :
- Academic Journal
- Accession number :
- 36116709
- Full Text :
- https://doi.org/10.1016/j.phrs.2022.106456